Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare Biotechnology
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > $5.6 Billion move into big pharma by Berkshire
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by Snowballgrowthon Jan 10, 2021 6:02am
117 Views
Post# 32262703

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:$5.6 Billion move into big pharma by Berkshire

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:$5.6 Billion move into big pharma by Berkshire
MrMugsy wrote: Wow ... on the contrary ... it is very different.
But it doesn't really matter - I know you are fairly new here.
I don't have a beef with you ... nor do I wish to start one.

Right now, the focus is on ATE and the next few months will determine if we have a bigger partnership brewing here.  Goodman is the gatekeeper of a deal - can he find value in the price for acquiring LATAM rights?




Acquiring rights is crucial AND get growth from the current portfolio is very important. Did they make a good estimation about GBT's pipeline? Remember that GBT previous management was listing very long list of potential products and many were supposed to be very promising. Did the previous VC owners too optimistic? I don't know but if they want to get new big rights vs the competition they also will have to get good growth from some products like Cresemba. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities